Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist
- PMID: 37536727
- DOI: 10.1183/13993003.01008-2023
Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist
Conflict of interest statement
Conflict of interest: M.M. Tunney reports grants from the European Union Innovative Medicines Initiative (grant agreement number 115721), Novartis, Spexis, Antabio and Shionogi. P. Wark reports no conflicts of interest.
Comment on
-
Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.Eur Respir J. 2023 Aug 3;62(2):2202153. doi: 10.1183/13993003.02153-2022. Print 2023 Aug. Eur Respir J. 2023. PMID: 37414422
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical